<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="29139c6f-70e7-44a8-8b6f-fff7a394ac03"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use <content styleCode="bold">MYXREDLIN</content> safely and effectively.  See full prescribing information for <content styleCode="bold">MYXREDLIN</content>.<br/>
      <content styleCode="bold">MYXREDLIN (insulin human) in sodium chloride injection, for intravenous use</content>
      <br/>Initial U.S. Approval: 2019</title>
   <effectiveTime value="20250307"/>
   <setId root="afca6e80-a802-49fb-a978-5fe28a173001"/>
   <versionNumber value="8"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="005083209" root="1.3.6.1.4.1.519.1"/>
            <name>Baxter Healthcare Corporation</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="194684502" root="1.3.6.1.4.1.519.1"/>
                        <name>Baxter Healthcare Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0126" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0126" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0126" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0126" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="STERILIZE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0126" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="9b3efcb5-421c-46d9-97b5-f058babf9505"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20190620"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0338-0126" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MYXREDLIN</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>insulin human</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="[iU]" value="1.00"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>INSULIN HUMAN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="1Y17CTI5SR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>INSULIN HUMAN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.412"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="22ADO53M6F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.29"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="593YOG76RN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="9"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43186" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CONTAINER"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="12"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0338-0126-12" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20190712"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA208157" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190712"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_184b055a-6473-4390-82f4-a1fa28b4ff80">
               <id root="184b055a-6473-4390-82f4-a1fa28b4ff80"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>MYXREDLIN is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.</paragraph>
               </text>
               <effectiveTime value="20190620"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>MYXREDLIN is a short-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus (<linkHtml href="#ID_184b055a-6473-4390-82f4-a1fa28b4ff80">1</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_18f4b4eb-2dc8-438d-af69-230f8f416148">
               <id root="18f4b4eb-2dc8-438d-af69-230f8f416148"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20190620"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Inspect MYXREDLIN visually before use.  It should appear clear and colorless.  Do not use MYXREDLIN if particulate matter or coloration is seen. (<linkHtml href="#ID_9adad454-2eed-4028-b039-904b8f76fb10">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Administer MYXREDLIN intravenously ONLY under medical supervision with close monitoring of blood glucose and potassium levels.<content styleCode="italics"/>(<linkHtml href="#ID_9adad454-2eed-4028-b039-904b8f76fb10">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Do not add supplementary medication or additives. (<linkHtml href="#ID_9adad454-2eed-4028-b039-904b8f76fb10">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Do not use in series connections. (<linkHtml href="#ID_9adad454-2eed-4028-b039-904b8f76fb10">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Do not shake or freeze.  Discard unused portion. (<linkHtml href="#ID_9adad454-2eed-4028-b039-904b8f76fb10">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Individualize dose based on metabolic needs, blood glucose monitoring results, and glycemic control goal. (<linkHtml href="#ID_e45edbd6-9c43-45e1-bd44-62033c4f2b43">2.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Dosage adjustments may be needed with changes in nutrition, renal, or hepatic function or during acute illness. (<linkHtml href="#ID_e45edbd6-9c43-45e1-bd44-62033c4f2b43">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_9adad454-2eed-4028-b039-904b8f76fb10">
                     <id root="9adad454-2eed-4028-b039-904b8f76fb10"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Administration Instructions </title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Inspect MYXREDLIN visually before use.  It should appear clear and colorless.  Do not use MYXREDLIN if particulate matter or coloration is seen.</item>
                           <item>
                              <caption>•</caption>Administer MYXREDLIN intravenously ONLY under medical supervision with close monitoring of blood glucose and potassium levels [see <linkHtml href="#ID_fed8b549-e4fd-46c3-b6f1-809e1dd749c2">Warnings and Precautions (5.2,</linkHtml>
                              <linkHtml href="#ID_2a4b7a4c-6e71-496b-be23-de9b6e0cf504"> 5.4)</linkHtml>].</item>
                           <item>
                              <caption>•</caption>Do not add supplementary medication or additives.</item>
                           <item>
                              <caption>•</caption>Do not use in series connections.</item>
                           <item>
                              <caption>•</caption>Do not shake.  Do not freeze.  Discard any unused portion.</item>
                        </list>
                     </text>
                     <effectiveTime value="20190620"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e45edbd6-9c43-45e1-bd44-62033c4f2b43">
                     <id root="e45edbd6-9c43-45e1-bd44-62033c4f2b43"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosage Information </title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Individualize and adjust the dosage of MYXREDLIN based on the individual's metabolic needs, blood glucose monitoring results, and glycemic control goal.</item>
                           <item>
                              <caption>•</caption>Dosage adjustments may be needed with changes in nutrition, changes in renal or hepatic function or during acute illness [see <linkHtml href="#ID_5d43ffc1-3851-4201-a8ed-123a33d89c58">Warnings and Precautions (5.1,</linkHtml>
                              <linkHtml href="#ID_fed8b549-e4fd-46c3-b6f1-809e1dd749c2"> 5.2)</linkHtml> and <linkHtml href="#ID_0e9a4946-e30d-4d4e-b888-0e40b036bc2f">Use in Specific Populations (8.6,</linkHtml>
                              <linkHtml href="#ID_6b63abdd-1cca-4ef8-938d-48453b387edf"> 8.7)</linkHtml>].</item>
                        </list>
                     </text>
                     <effectiveTime value="20190620"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6016d008-48db-4acc-a387-bc92f886aa50">
                     <id root="6016d008-48db-4acc-a387-bc92f886aa50"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Dosage Adjustment due to Drug Interactions </title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Dosage adjustment may be needed when MYXREDLIN is used concomitantly with certain drugs [see <linkHtml href="#ID_ce0531b6-647d-4540-b8a4-ec80c0e4c1b1">Drug Interactions (7)</linkHtml>].</item>
                        </list>
                     </text>
                     <effectiveTime value="20190620"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_84c9d296-cfd2-4371-b248-0efea8c61d2b">
               <id root="84c9d296-cfd2-4371-b248-0efea8c61d2b"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Injection:  100 units insulin human in 100 mL of 0.9% sodium chloride (1 unit per mL) as a clear, colorless solution in a single-dose container.</paragraph>
               </text>
               <effectiveTime value="20190620"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection:  100 units insulin human in 100 mL of 0.9% sodium chloride (1 unit/mL) in a single-dose container (<linkHtml href="#ID_84c9d296-cfd2-4371-b248-0efea8c61d2b">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_32df6bc3-f185-4a95-96a7-b8e2529c742c">
               <id root="32df6bc3-f185-4a95-96a7-b8e2529c742c"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>MYXREDLIN is contraindicated:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>During episodes of hypoglycemia</item>
                     <item>
                        <caption>•</caption>In patients with hypersensitivity to insulin human or any of the excipients in MYXREDLIN</item>
                  </list>
               </text>
               <effectiveTime value="20190620"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>During episodes of hypoglycemia (<linkHtml href="#ID_32df6bc3-f185-4a95-96a7-b8e2529c742c">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Hypersensitivity to insulin human or any of the excipients in MYXREDLIN (<linkHtml href="#ID_32df6bc3-f185-4a95-96a7-b8e2529c742c">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_297304bc-fb5d-4774-b69c-d3596bbbe7e4">
               <id root="297304bc-fb5d-4774-b69c-d3596bbbe7e4"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20190620"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Hyper- or Hypoglycemia with Changes in Insulin Regimen:</content>  Carry out under close medical supervision and increase frequency of blood glucose monitoring. (<linkHtml href="#ID_5d43ffc1-3851-4201-a8ed-123a33d89c58">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Hypoglycemia:</content>  May be life-threatening.  Factors which may increase the risk include changes in nutrition and co-administered medication and patients with renal or hepatic impairment.  Increased frequency of blood glucose monitoring is recommended in patients at increased risk. (<linkHtml href="#ID_fed8b549-e4fd-46c3-b6f1-809e1dd749c2">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Hypersensitivity Reactions:</content>  Severe, life-threatening, generalized allergy, including anaphylaxis, can occur.  Discontinue MYXREDLIN, monitor, and treat if indicated. (<linkHtml href="#ID_f431b081-c2a1-4aba-a078-981f2f48a651">5.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Hypokalemia:</content>  May be life-threatening.  Monitor potassium levels and treat if indicated. (<linkHtml href="#ID_2a4b7a4c-6e71-496b-be23-de9b6e0cf504">5.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Fluid Retention and Heart Failure with Concomitant Use of Thiazolidinediones (TZDs):</content>  Observe for signs and symptoms of heart failure; consider dosage reduction or discontinuation if heart failure occurs. (<linkHtml href="#ID_407cc62d-505d-4e9d-b047-9bac2bcbca32">5.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_5d43ffc1-3851-4201-a8ed-123a33d89c58">
                     <id root="5d43ffc1-3851-4201-a8ed-123a33d89c58"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen </title>
                     <text>
                        <paragraph>Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia [see <linkHtml href="#ID_fed8b549-e4fd-46c3-b6f1-809e1dd749c2">Warnings and Precautions (5.2)</linkHtml>] or hyperglycemia.  These changes should be made cautiously and under close medical supervision and the frequency of blood glucose monitoring should be increased.</paragraph>
                     </text>
                     <effectiveTime value="20190620"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_fed8b549-e4fd-46c3-b6f1-809e1dd749c2">
                     <id root="fed8b549-e4fd-46c3-b6f1-809e1dd749c2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hypoglycemia </title>
                     <text>
                        <paragraph>Hypoglycemia is the most common adverse reaction of all insulins, including MYXREDLIN.  Severe hypoglycemia can cause seizures, may lead to unconsciousness, may be life threatening or cause death.  Hypoglycemia can impair concentration ability and reaction time.</paragraph>
                        <paragraph>Hypoglycemia can happen suddenly and symptoms may differ in each individual and change over time in the same individual.  Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see <linkHtml href="#ID_ce0531b6-647d-4540-b8a4-ec80c0e4c1b1">Drug Interactions (7)</linkHtml>], or in patients who experience recurrent hypoglycemia.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk Factors for Hypoglycemia<br/>
                           </content>Factors which may increase the risk of hypoglycemia include changes in nutrition and co-administered medication [see <linkHtml href="#ID_ce0531b6-647d-4540-b8a4-ec80c0e4c1b1">Drug Interactions (7)</linkHtml>].  Patients with renal or hepatic impairment may be at higher risk of hypoglycemia [see <linkHtml href="#ID_0e9a4946-e30d-4d4e-b888-0e40b036bc2f">Use in Specific Populations (8.6,</linkHtml>
                           <linkHtml href="#ID_6b63abdd-1cca-4ef8-938d-48453b387edf"> 8.7)</linkHtml>].</paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk Mitigation Strategies for Hypoglycemia</content>
                           <br/>Patients and caregivers must be educated to recognize hypoglycemia.  In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.</paragraph>
                     </text>
                     <effectiveTime value="20190620"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f431b081-c2a1-4aba-a078-981f2f48a651">
                     <id root="f431b081-c2a1-4aba-a078-981f2f48a651"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Hypersensitivity and Allergic Reactions </title>
                     <text>
                        <paragraph>Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with MYXREDLIN.  Generalized allergy to insulin may manifest as a whole body rash (including pruritus), dyspnea, wheezing, hypotension, tachycardia, or diaphoresis.  If hypersensitivity reactions occur, discontinue MYXREDLIN; treat per standard of care and monitor until symptoms and signs resolve.  MYXREDLIN is contraindicated in patients who have had hypersensitivity reactions to insulin human or any of the excipients in MYXREDLIN [see <linkHtml href="#ID_32df6bc3-f185-4a95-96a7-b8e2529c742c">Contraindications (4)</linkHtml>].</paragraph>
                     </text>
                     <effectiveTime value="20190620"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2a4b7a4c-6e71-496b-be23-de9b6e0cf504">
                     <id root="2a4b7a4c-6e71-496b-be23-de9b6e0cf504"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Hypokalemia </title>
                     <text>
                        <paragraph>All insulins, including MYXREDLIN, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia.  Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death.  Monitor potassium levels and treat if indicated.</paragraph>
                     </text>
                     <effectiveTime value="20190620"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_407cc62d-505d-4e9d-b047-9bac2bcbca32">
                     <id root="407cc62d-505d-4e9d-b047-9bac2bcbca32"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma agonists </title>
                     <text>
                        <paragraph>Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin.  Fluid retention may lead to or exacerbate heart failure.  Patients treated with insulin, including MYXREDLIN, and a PPAR-gamma agonist should be observed for signs and symptoms of heart failure.  If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist must be considered.</paragraph>
                     </text>
                     <effectiveTime value="20190620"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_240d64a1-f245-4e29-aec3-6296a9f779b5">
               <id root="240d64a1-f245-4e29-aec3-6296a9f779b5"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following adverse reactions are also discussed elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Hypoglycemia [see <linkHtml href="#ID_fed8b549-e4fd-46c3-b6f1-809e1dd749c2">Warnings and Precautions (5.2)</linkHtml>]</item>
                     <item>
                        <caption>•</caption>Hypersensitivity Reactions [see <linkHtml href="#ID_f431b081-c2a1-4aba-a078-981f2f48a651">Warnings and Precautions (5.3)</linkHtml>]</item>
                     <item>
                        <caption>•</caption>Hypokalemia [see <linkHtml href="#ID_2a4b7a4c-6e71-496b-be23-de9b6e0cf504">Warnings and Precautions (5.4)</linkHtml>]</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Adverse Reactions from Clinical Studies or Postmarketing Reports<br/>
                     </content>The following additional adverse reactions have been identified during clinical studies or from postmarketing reports with use of insulin human injection.  Because some of these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Adverse reactions associated with insulin initiation and glucose control intensification<br/>
                     </content>Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder, worsening of diabetic retinopathy, and acute painful peripheral neuropathy.  Over the long-term, improved glycemic control decreases the risk of diabetic retinopathy and neuropathy.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Hypersensitivity reactions<br/>
                     </content>Severe, life-threatening, generalized allergy, including anaphylaxis.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Hypoglycemia<br/>
                     </content>Hypoglycemia is the most commonly observed adverse reaction with MYXREDLIN.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Hypokalemia<br/>
                     </content>MYXREDLIN can cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Peripheral edema<br/>
                     </content>Insulins, including MYXREDLIN, may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Weight gain<br/>
                     </content>Weight gain can occur with insulin therapies, including MYXREDLIN, and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Immunogenicity<br/>
                     </content>As with all therapeutic peptides, insulin administration may cause anti-insulin antibodies to form.  Increases in titers of anti-insulin antibodies that react with human insulin have been observed in patients treated with subcutaneous insulin human injection.</paragraph>
               </text>
               <effectiveTime value="20190620"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Adverse reactions observed with insulin human injection include hypoglycemia, allergic reactions, weight gain and edema (<linkHtml href="#ID_240d64a1-f245-4e29-aec3-6296a9f779b5">6</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content styleCode="bold">Baxter Healthcare at 1-866-888-2472</content>
                           <content styleCode="bold"> or FDA at 1-800-FDA-1088 or </content>
                           <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_ce0531b6-647d-4540-b8a4-ec80c0e4c1b1">
               <id root="0045025f-6094-42e7-9e75-f22ddc74e13d"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <text>
                  <table styleCode="Noautorules" width="100%">
                     <caption>Table 1:  Clinically Significant Drug Interactions with MYXREDLIN</caption>
                     <col width="16%"/>
                     <col width="84%"/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Drugs that May Increase the Risk of Hypoglycemia</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Drugs:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Intervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>Dose adjustment and increased frequency of glucose monitoring may be required when MYXREDLIN is co-administered with these drugs.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Drugs that May Decrease the Blood Glucose Lowering Effect of MYXREDLIN</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Drugs:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Intervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>Dose adjustment and increased frequency of glucose monitoring may be required when MYXREDLIN is co-administered with these drugs.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Drugs that May Increase or Decrease the Blood Glucose Lowering Effect of MYXREDLIN</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Drugs:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>Alcohol, beta-blockers, clonidine, and lithium salts.  Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Intervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>Dose adjustment and increased frequency of glucose monitoring may be required when MYXREDLIN is co-administered with these drugs.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Drugs that May Blunt Signs and Symptoms of Hypoglycemia</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Drugs:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>Beta-blockers, clonidine, guanethidine, and reserpine.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Intervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>Increased frequency of glucose monitoring may be required when MYXREDLIN is co-administered with these drugs.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20200604"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Drugs that may increase the risk of hypoglycemia:</content>  antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. (<linkHtml href="#ID_ce0531b6-647d-4540-b8a4-ec80c0e4c1b1">7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Drugs that may decrease the blood glucose lowering effect:</content>  atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (<linkHtml href="#ID_ce0531b6-647d-4540-b8a4-ec80c0e4c1b1">7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Drugs that may increase or decrease the blood glucose lowering effect:</content>  Alcohol, beta-blockers, clonidine, lithium salts, and pentamidine. (<linkHtml href="#ID_ce0531b6-647d-4540-b8a4-ec80c0e4c1b1">7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Drugs that may blunt the signs and symptoms of hypoglycemia:</content>  beta-blockers, clonidine, guanethidine, and reserpine. (<linkHtml href="#ID_ce0531b6-647d-4540-b8a4-ec80c0e4c1b1">7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_4290a7c4-1b86-4d4b-bcf6-72bbeae0e8a6">
               <id root="4290a7c4-1b86-4d4b-bcf6-72bbeae0e8a6"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20190620"/>
               <component>
                  <section ID="ID_322a6c56-9529-4761-a494-209ebb97235f">
                     <id root="322a6c56-9529-4761-a494-209ebb97235f"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Risk Summary</content>
                           </content>
                           <br/>Available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes <content styleCode="italics">(see Data)</content>.  There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy <content styleCode="italics">(see Clinical Considerations)</content>.  Animal reproduction studies were not performed.</paragraph>
                        <paragraph>The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a HbA1c &gt;7 and has been reported to be as high as 20-25% in women with a HbA1c &gt;10.  The estimated background risk of miscarriage for the indicated population is unknown.  In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Clinical Considerations</content>
                              <br/>Disease-associated maternal and/or embryo/fetal risk</content>
                        </paragraph>
                        <paragraph>Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications.  Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Data</content>
                              <br/>Human Data</content>
                        </paragraph>
                        <paragraph>While available studies cannot definitively establish the absence of risk, published data from retrospective studies, open-label, randomized, parallel studies and meta-analyses have not established an association with human insulin use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes.  All available studies have methodological limitations including lack of blinding, unclear methods of randomization, and small sample size.</paragraph>
                     </text>
                     <effectiveTime value="20190620"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_92a6a705-5320-4005-81b7-6480623828e8">
                     <id root="92a6a705-5320-4005-81b7-6480623828e8"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Risk Summary</content>
                           </content>
                           <br/>Available data from published literature suggest that exogenous human insulin products, including insulin human injection, are transferred into human milk.  There are no adverse reactions reported in the breastfed infants in the literature.  There are no data on the effects of exogenous human insulin products, including MYXREDLIN, on milk production.  The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for MYXREDLIN and any potential adverse effects on the breastfed infant from MYXREDLIN or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20190620"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1b998ff0-d6ed-4e4f-a985-539fc8d85112">
                     <id root="1b998ff0-d6ed-4e4f-a985-539fc8d85112"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>MYXREDLIN is indicated to improve glycemic control in pediatric patients with diabetes mellitus.</paragraph>
                        <paragraph>The dosage of MYXREDLIN must be individualized in pediatric patients based on metabolic needs and frequent monitoring of blood glucose to reduce the risk of hypoglycemia [see <linkHtml href="#ID_e45edbd6-9c43-45e1-bd44-62033c4f2b43">Dosage and Administration (2.2)</linkHtml> and <linkHtml href="#ID_fed8b549-e4fd-46c3-b6f1-809e1dd749c2">Warnings and Precautions (5.2)</linkHtml>].</paragraph>
                     </text>
                     <effectiveTime value="20190620"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_abc5fc6c-a766-4f48-8741-dff2689573fb">
                     <id root="abc5fc6c-a766-4f48-8741-dff2689573fb"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>The effect of age on the pharmacokinetics and pharmacodynamics of insulin human injection has not been studied.</paragraph>
                        <paragraph>Elderly patients using MYXREDLIN, may be at increased risk of hypoglycemia due to co-morbid disease [see <linkHtml href="#ID_fed8b549-e4fd-46c3-b6f1-809e1dd749c2">Warnings and Precautions (5.2)</linkHtml>].</paragraph>
                     </text>
                     <effectiveTime value="20190620"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0e9a4946-e30d-4d4e-b888-0e40b036bc2f">
                     <id root="0e9a4946-e30d-4d4e-b888-0e40b036bc2f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment </title>
                     <text>
                        <paragraph>The effect of renal impairment on the pharmacokinetics and pharmacodynamics of MYXREDLIN has not been studied.  Patients with renal impairment are at increased risk of hypoglycemia and may require more frequent MYXREDLIN dose adjustment and more frequent blood glucose monitoring [see <linkHtml href="#ID_fed8b549-e4fd-46c3-b6f1-809e1dd749c2">Warnings and Precautions (5.2)</linkHtml>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190620"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6b63abdd-1cca-4ef8-938d-48453b387edf">
                     <id root="6b63abdd-1cca-4ef8-938d-48453b387edf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Hepatic Impairment </title>
                     <text>
                        <paragraph>The effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of MYXREDLIN has not been studied.  Patients with hepatic impairment are at increased risk of hypoglycemia and may require more frequent MYXREDLIN dose adjustment and more frequent blood glucose monitoring [see <linkHtml href="#ID_fed8b549-e4fd-46c3-b6f1-809e1dd749c2">Warnings and Precautions (5.2)</linkHtml>].</paragraph>
                     </text>
                     <effectiveTime value="20190620"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3bf2a39a-2872-441d-bf67-8a5340140a64">
               <id root="3bf2a39a-2872-441d-bf67-8a5340140a64"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>Excess insulin administration may cause hypoglycemia and hypokalemia.  More severe episodes with coma, seizure, or neurologic impairment can be treated with intramuscular or subcutaneous glucagon or intravenous glucose.  Sustained monitoring may be necessary because hypoglycemia may recur after apparent clinical recovery.  Hypokalemia must be corrected appropriately.  [see <linkHtml href="#ID_fed8b549-e4fd-46c3-b6f1-809e1dd749c2">Warnings and Precautions (5.2,</linkHtml>
                     <linkHtml href="#ID_2a4b7a4c-6e71-496b-be23-de9b6e0cf504"> 5.4)</linkHtml>]</paragraph>
               </text>
               <effectiveTime value="20190620"/>
            </section>
         </component>
         <component>
            <section ID="ID_4251d79c-1011-4aff-97fc-812eddb9b3f3">
               <id root="93594ecb-abbb-47a9-81b9-0842cd408440"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Insulin human is a short-acting human insulin.  It is a polypeptide hormone and is produced by recombinant DNA technology, utilizing <content styleCode="italics">Pichia pastoris </content>(a yeast) as the production organism.  Insulin human is regular human insulin and has the empirical formula C<sub>257</sub>H<sub>383</sub>N<sub>65</sub>O<sub>77</sub>S<sub>6</sub> and a molecular weight of 5808.</paragraph>
                  <paragraph>Figure 1:  Structural formula of Insulin Human</paragraph>
                  <renderMultiMedia ID="id902796387" referencedObject="ID_1b498392-3743-4243-ad30-0c3c1d4c5e57"/>
                  <paragraph>MYXREDLIN (insulin human) in 0.9% sodium chloride injection for intravenous use is a sterile, preservative-free, nonpyrogenic, clear, aqueous, and colorless solution supplied in a 100 mL GALAXY single-dose container.  MYXREDLIN contains 100 units of insulin human in 100 milliliters of 0.9% sodium chloride injection.  Each milliliter of solution contains 1 unit Insulin Human, USP; 0.412 mg Dibasic Sodium Phosphate Anhydrous, USP; 0.29 mg Monobasic Sodium Phosphate Monohydrate, USP; 9 mg Sodium Chloride, USP; and Water for Injection, USP.  The pH range is 6.5-7.2.</paragraph>
               </text>
               <effectiveTime value="20200604"/>
               <component>
                  <observationMedia ID="ID_1b498392-3743-4243-ad30-0c3c1d4c5e57">
                     <text>Structural Formula Insulin Human</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a18affdf-7b88-43ae-a119-dfe7fc5ed8c0">
               <id root="a18affdf-7b88-43ae-a119-dfe7fc5ed8c0"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20190620"/>
               <component>
                  <section ID="ID_b4dab27f-846f-4a4f-ba46-4545b1714163">
                     <id root="b4dab27f-846f-4a4f-ba46-4545b1714163"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>The primary activity of insulin, including MYXREDLIN is the regulation of glucose metabolism.  Insulins lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production.  Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.</paragraph>
                     </text>
                     <effectiveTime value="20190620"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_018e46b9-62d4-4eea-a17b-67015c2123d1">
                     <id root="018e46b9-62d4-4eea-a17b-67015c2123d1"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>MYXREDLIN is a short-acting insulin.  The time course of insulin action (i.e., glucose lowering) may vary considerably in different individuals, within the same individual, and different doses.  In a double-blind, randomized, crossover, euglycemic glucose clamp study described below, the average onset of action, defined as start of intravenous glucose infusion during the clamp, was approximately 21 minutes after starting of the intravenous infusion administration.  The glucose infusion rate gradually increased to a maximum response of 13.7 mg/kg/min after 5 hours of human insulin infusion.</paragraph>
                     </text>
                     <effectiveTime value="20190620"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_45cf0af4-a787-4166-b44a-292f44bf04a8">
                     <id root="45cf0af4-a787-4166-b44a-292f44bf04a8"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>In a double-blind, randomized, crossover, euglycemic glucose clamp study, fifty eight healthy male subjects between 19 and 50 years of age received an intravenous infusion of either MYXREDLIN or another human insulin at 1 milliUnit/kg/min for 6 hours (0.36 units/kg total dose).  On average, insulin concentrations of about 300 pM were attained approximately from 1.5 hours to 6 hours after starting intravenous infusion of MYXREDLIN, followed by a return to the baseline level 1.5 hours after stopping intravenous infusion.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism and Elimination</content>
                        </paragraph>
                        <paragraph>The mean terminal half-life from concentration data after stopping the intravenous infusion was estimated to be 23.4 minutes in healthy volunteers.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Population</content>
                        </paragraph>
                        <paragraph>The effects of gender, age, obesity, renal and hepatic impairment on the pharmacodynamics and pharmacokinetics of insulin human injection have not been studied.</paragraph>
                     </text>
                     <effectiveTime value="20190620"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_39f1f168-1bc8-4e84-a047-d8f161b28ef2">
               <id root="39f1f168-1bc8-4e84-a047-d8f161b28ef2"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20190620"/>
               <component>
                  <section ID="ID_826196cd-f9f9-459b-af58-8bf5bb99ab18">
                     <id root="826196cd-f9f9-459b-af58-8bf5bb99ab18"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>Standard 2-year carcinogenicity studies in animals have not been performed to evaluate the carcinogenic potential of insulin human injection.</paragraph>
                        <paragraph>Human insulin is not mutagenic in the following <content styleCode="italics">in vitro</content> tests:  The chromosomal aberration assay in human lymphocytes, the micronucleus assay in mouse polychromatic erythrocytes, and the mutation frequency assay in Chinese hamster cells.</paragraph>
                        <paragraph>Standard reproduction and teratology studies in animals, including fertility assessments have not been conducted with insulin human injection.</paragraph>
                     </text>
                     <effectiveTime value="20190620"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_4cf66675-7a75-474d-9e7a-3dddbc7cf47b">
               <id root="c37ef1f5-9495-4053-8cfe-65a902f9485c"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <effectiveTime value="20250307"/>
               <component>
                  <section ID="ID_cc88d5d6-520b-4b91-84d2-f66fce6f327c">
                     <id root="1b549262-9f95-4bcf-a4ae-a4b904d3df9b"/>
                     <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
                     <title>16.1 How Supplied </title>
                     <text>
                        <paragraph>MYXREDLIN (insulin human) in 0.9% sodium chloride injection contains 100 units/100 mL (1 unit/mL) of insulin human in 0.9% sodium chloride and is a clear, colorless solution available as:</paragraph>
                        <list listType="ordered">
                           <item>
                              <caption> </caption>100 mL single-dose GALAXY container, package of 12, NDC 0338-0126-12</item>
                        </list>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_4e796469-c2bb-4618-8f58-e65bce48568f">
                     <id root="e113cd73-d18c-4043-b614-77d5631fa289"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2 Storage and Handling </title>
                     <text>
                        <paragraph>Store MYXREDLIN in the refrigerator (36°F to 46°F [2°C to 8°C]) in the original carton to protect from light.  Do not use after the expiration date printed on the carton and container label.</paragraph>
                        <paragraph>If needed, MYXREDLIN may be removed from the original carton and stored at room temperature up to 77°F (25°C) for up to 30 days.  Once stored at room temperature, do not place back in the refrigerator.  Discard MYXREDLIN after 30 days if stored at room temperature.</paragraph>
                        <paragraph>Do not freeze and do not use MYXREDLIN if it has been frozen.  Do not shake.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_1f1db675-58db-4ec4-84bd-9aa6398e4d60">
               <id root="1f1db675-58db-4ec4-84bd-9aa6398e4d60"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">Hypoglycemia</content>
                     </content>
                  </paragraph>
                  <paragraph>Inform patients that hypoglycemia is the most common adverse reaction with insulin.  Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">Hypersensitivity Reactions</content>
                     </content>
                  </paragraph>
                  <paragraph>Advise patients that hypersensitivity reactions have occurred with insulin human injection [see <linkHtml href="#ID_f431b081-c2a1-4aba-a078-981f2f48a651">Warnings and Precautions (5.3)</linkHtml>].</paragraph>
               </text>
               <effectiveTime value="20190620"/>
            </section>
         </component>
         <component>
            <section ID="ID_9d4dde3c-b3ab-4b46-ac6e-17d757fad41b">
               <id root="c13cd9e9-6013-4c82-94e1-7072500adadf"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured by:<br/>
                     <content styleCode="bold">Baxter Healthcare Corporation<br/>
                     </content>Deerfield, IL 60015 USA</paragraph>
                  <paragraph>U.S. License Number 0140</paragraph>
                  <paragraph>Baxter, Galaxy and Myxredlin are registered trademarks of Baxter International Inc.</paragraph>
                  <paragraph>07-19-01-720</paragraph>
               </text>
               <effectiveTime value="20250307"/>
            </section>
         </component>
         <component>
            <section ID="ID_a76761bb-66d9-467f-9bac-6dd1603efa19">
               <id root="8f74929a-f65a-44f7-9721-eb27c0de45d1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL </title>
               <text>
                  <renderMultiMedia ID="id2035536429" referencedObject="ID_28246846-3404-4dfc-b3f2-3c42662cff15"/>
                  <content styleCode="bold">
                     <renderMultiMedia ID="id-1828047998" referencedObject="ID_70113c44-c5d1-4e41-b1d6-17168febe4f8"/>
                  </content>
                  <content styleCode="bold">
                     <renderMultiMedia ID="id-792677792" referencedObject="ID_359fa380-9774-4b8f-8888-dfcf3e5d13b0"/>
                  </content>
                  <paragraph>
                     <content styleCode="bold">Container Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0338-0126-12      Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">MYXREDLIN<br/>Insulin Human<br/>in 0.9% Sodium Chloride Injection<br/>100 units per 100 mL<br/>(1 unit / mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 mL Single-Dose GALAXY container      (REGULAR) Insulin Human<br/>Discard unused portion      Sterile Nonpyrogenic</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Infusion Only</content>
                  </paragraph>
                  <paragraph>Cautions: Do not add supplemental medication or additives.<br/>Must not be used in series connections. Check for minute leaks and<br/>solution clarity.</paragraph>
                  <paragraph>Each mL contains: 1 unit Insulin Human, USP; 0.412 mg Dibasic Sodium<br/>Phosphate Anhydrous, USP; 0.29 mg Monobasic Sodium Phosphate<br/>Monohydrate, USP; 9 mg Sodium Chloride, USP; and Water for Injection,<br/>USP.</paragraph>
                  <paragraph>Dosage: See prescribing information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Store refrigerated at 36°F to 46°F (2°C to 8°C) in the original carton to<br/>protect from light. Do Not Shake. Do Not Freeze.</content>
                  </paragraph>
                  <paragraph>If needed, may store at room temperature up to 77°F (25°C) up to<br/>30 days. Discard after 30 days if stored at room temperature.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Baxter logo       </content>Code 2G3322</content>
                  </paragraph>
                  <paragraph>Baxter, Galaxy and Myxredlin are registered trademarks of <br/>Baxter International Inc.<br/>
                     <content styleCode="bold">Baxter Healthcare Corporation<br/>
                     </content>Deerfield, IL 60015 USA<br/>U.S. License no. 0140</paragraph>
                  <paragraph>Product of USA<br/>07-34-00-2341</paragraph>
                  <paragraph>CONTAINS INSULIN</paragraph>
                  <paragraph>BAR CODE<br/>POSITION ONLY UPC-A</paragraph>
                  <paragraph>303380126125</paragraph>
                  <renderMultiMedia ID="id1428920309" referencedObject="ID_42620fa1-d5ba-4d37-a4eb-6d9c9c03a7c7"/>
                  <content styleCode="bold">
                     <renderMultiMedia ID="id318157322" referencedObject="ID_8ec6c150-0889-42c1-9d5c-b02a8e52883b"/>
                  </content>
                  <paragraph>
                     <content styleCode="bold">Carton Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">MYXREDLIN<br/>Insulin Human<br/>in 0.9% Sodium Chloride Injection <br/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">CONTAINS INSULIN HUMAN<br/>100 units per 100 mL (1 unit/mL)<br/>For Intravenous Infusion Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">MYXREDLIN<br/>Insulin Human<br/>in 0.9% Sodium Chloride Injection <br/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">CONTAINS INSULIN HUMAN<br/>100 units per 100 mL (1 unit/mL)<br/>For Intravenous Infusion Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0338-0126-12</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">MYXREDLIN<br/>Insulin Human<br/>in 0.9% Sodium Chloride Injection <br/>100 units per 100 mL<br/>(1 unit / mL)</content>
                  </paragraph>
                  <paragraph>UNVARNISHED AREA FOR ON-LINE<br/>PRINTING OF LOT AND EXP</paragraph>
                  <paragraph>UPC-A<br/>Bar Code<br/>Placement</paragraph>
                  <paragraph>Sterile, Nonpyrogenic</paragraph>
                  <paragraph>Each mL contains: 1 unit Insulin Human, USP; 0.412 mg Dibasic Sodium Phosphate Anhydrous,<br/>USP; 0.29 mg Monobasic Sodium Phosphate Monohydrate, USP; 9 mg Sodium Chloride, USP;<br/>and Water for Injection, USP.  No preservative.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Dosage: </content>For Intravenous Infusion Only. See prescribing information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Caution: </content>Do not add supplemental medication or additives.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Store refrigerated at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light.<br/>Do Not Shake. Do Not Freeze.</content>
                  </paragraph>
                  <paragraph>If needed, may store MYXREDLIN at room temperature up to 77°F (25°C) up to 30 days.<br/>Once stored at room temperature, do not place back in the refrigerator.<br/>Discard after 30 days if stored at room temperature.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Discard 30 days after storing at room temperature. Discard After:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(Month) (Day) (Year)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(to be completed by dispensing pharmacist)</content>
                  </paragraph>
                  <paragraph>Baxter, Galaxy and Myxredlin are registered trademarks of Baxter International Inc.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Baxter Healthcare Corporation</content>
                  </paragraph>
                  <paragraph>Deerfield, IL 60015 USA</paragraph>
                  <paragraph>U.S. License no. 0140</paragraph>
                  <paragraph>Product of USA<br/>
                     <content styleCode="bold">07-01-00-0676</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">MYXREDLIN</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Insulin Human<br/>in 0.9% Sodium Chloride Injection</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">CONTAINS INSULIN HUMAN<br/>100 units per 100 mL (1 unit/mL)</content>
                     <br/>
                     <content styleCode="bold">For Intravenous Infusion Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">MYXREDLIN</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Insulin Human<br/>in 0.9% Sodium Chloride Injection</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">CONTAINS INSULIN HUMAN<br/>100 units per 100 mL (1 unit/mL)</content>
                     <br/>
                     <content styleCode="bold">For Intravenous Infusion Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0338-0126-12       </content>Rx Only</paragraph>
                  <paragraph>
                     <content styleCode="bold">MYXREDLIN<br/>Insulin Human<br/>in 0.9% Sodium Chloride Injection<br/>100 units per 100 mL <br/>(1 unit/mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Infusion Only<br/>(REGULAR) Insulin Human</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">USE CARTON TO PROTECT CONTENTS<br/>FROM LIGHT WHILE REFRIGERATED</content>
                  </paragraph>
                  <paragraph>Code 2G3322</paragraph>
                  <paragraph>1 Single-Dose GALAXY container<br/>Discard unused portion</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Baxter Logo</content>
                     </content>
                  </paragraph>
                  <paragraph>G </paragraph>
               </text>
               <effectiveTime value="20250307"/>
               <component>
                  <observationMedia ID="ID_28246846-3404-4dfc-b3f2-3c42662cff15">
                     <text>Representative Container Label 0338-0126-12 panel 1 of 3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_70113c44-c5d1-4e41-b1d6-17168febe4f8">
                     <text>Representative Container Label 0338-0126-12 panel 2 of 3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_359fa380-9774-4b8f-8888-dfcf3e5d13b0">
                     <text>Representative Container Label 0338-0126-12 panel 3 of 3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_42620fa1-d5ba-4d37-a4eb-6d9c9c03a7c7">
                     <text>Representative Carton Label 0338-0126-12 1 of 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_8ec6c150-0889-42c1-9d5c-b02a8e52883b">
                     <text>Representative Carton Label 0338-0126-12 2 of 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>